Restless Legs Syndrome: Medical Treatments
The question
To ask the Secretary of State for Health and Social Care, what assessment NHS England has made of the potential risks of dopamine agonists as a treatment for restless leg syndrome.
Answered by Karin Smyth
NHS England has made no assessment. The Medicines and Healthcare products Regulatory Agency (MHRA) assesses all medicines before they are licensed in the United Kingdom, with regard to quality, safety, and efficacy. The licensed dopamine agonist medicines that are indicated for the treatment of restless leg syndrome (RLS) are ropinirole, pramipexole, and rotigotine.
The National Institute for Health and Care Excellence recently revised its Clinical Knowledge Summary (CKS) on the diagnosis and clinical management of RLS, which was updated in February 2025, and which can be used as a source of information for healthcare professionals. This CKS is available at the following link:
https://cks.nice.org.uk/topics/restless-legs-syndrome/
Decisions about what medicines to prescribe are made by the doctor or healthcare professional responsible for that part of the patient’s care. Prescribers are accountable for their prescribing decisions. Prescribers must always satisfy themselves that the medicines they consider appropriate for their patients can be safely prescribed, and that they take account of appropriate national guidance on clinical effectiveness, as well as the local commissioning decisions of their respective integrated care boards.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →